Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Post by grosdavidon May 05, 2020 3:07pm

187 Views

Post# 30989283

Hard news to swallow, but you guys keep

forget the medium/long term play here...I know we want the quick bucks easily, but today is not for that.

JT announced funding, AGN can clearly apply in the next upcoming weeks.

I'm guessing AGN needs money now to advance. A PP was announced last week, now it was lowered. Still, this is hard for everyone, the main goal hasn't changed.

David

Bullboard Posts

Understanding tax loss season and the “Santa Claus rally”